Abionyx Pharma, a new generation biotech company dedicated to the discovery and development of therapies based on the world’s only natural recombinant ApoA-I, reported the successful GMP industrial biomanufacturing of a batch of CER-001 using an innovative and robust method. In a statement, the company said that the success confirms the relevance of the strategy to relocate biomanufacturing to France, which was implemented four years ago, not only to contribute to the country’s in...